MET and neoplasm: Capmatinib strongly inhibited tumor growth in both the NF1-MET and NF1-MET;sgP53 models (Fig. 2F; Supplementary Fig. 4F), however only the NF1-MET tumors regressed on treatment (p-value = 0.0083), while the NF-MET;sgP53 tumors remained stable throughout treatment, with a subset of tumors actually showing increased growth (Fig. 2F, G; Supplementary Fig. 4F).